References
- Barrett S. P., Darredeau C., Bordy L. E., Pihl R. O. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 2005; 50: 457–461
- Barrett S. P., Darredeau C., Pihl R. O. Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacology 2006; 21: 255–263
- Batten H. L., Prottas J. M., Horgan C. M., Simon L. J., Larson M. J., Elliott E. A., et al. Drug services research survey. Phase II final report. Bigel Institute for Health Policy, Brandeis University, Waltham 1992
- Bird S. Prescribing schedule 8 drugs. Australian Family Physician 2006; 35: 59–60
- Boeuf O., Lapeyre‐Mestre M. Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Safety 2007; 30: 265–276
- Bollinger S. L., Bush C., Chenault K. I., Curtis J. L., Dimon J., Dolan P. R., et al. Under the counter: The diversion and abuse of controlled prescription drugs in the U.S. 2005, The National Center on Addiction and Substance Abuse at Columbia University (CASA). Accessed from http://www.casacolumbia.org/absolutenm/arbiclefiles/380‐Under%20the%20Counter%20‐%20Diversion.pdf
- Brushwood D. B., Kimberlin C. A. Media coverage of controlled substance diversion through theft or loss. Journal of the American Pharmaceutical Association 2004; 44: 439–444
- Canadian Center on Substance Abuse. Prescription Drug Abuse FAQs. 2007, Accessed from http://www.ccsa.ca/2006%20CCSA%20Documents/ccsa‐011332‐2006.pdf
- Fischer B., Brissette S., Brochu S., Bruneau J., El Guebaly N., Noel L., et al. Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. Canadian Medical Association Journal 2004; 171: 235–239
- Fischer B., Rehm J., Patra J., Cruz M. F. Changes in illicit opioid use across Canada. Canadian Medical Association Journal 2006; 175: 1385–1387
- Foran A. NSPMP's Board Resolution Regarding on‐line System. PMP Bulletin. 2007, Prescription Monitoring in Nova Scotia. Halifax, NS, Canada. Avaliable on line: http://www.cpsns.ns.ca/2007‐july‐pmp‐bulletin.pdf
- Foran A. PMP Bulletin. 2006, Prescription Monitoring in Nova Scotia. Halifax, NS, Canada. Accessed from http://www.cpsns.ns.ca/2006‐may‐pmp‐bulletin.pdf
- Goodwin R. D., Hasin D. S. Sedative use and misuse in the United States. Addiction 2002; 97: 555–562
- Grzybowski S. The black market in prescription drugs. Lancet 2004; 364: 28–29
- Health Canada. Abuse and diversion of controlled substances: A guide for health professionals. 2006, Accessed from http://www.pdbns.ca/Resources/Docs/Health%20Canada%20‐%20A%20Guide%20for%20Health%20Professionals%20‐%20English.pdf
- Huang B., Dawson D. A., Stinson F. S., Hasin D. S., Ruan W. J., Saha T. D., et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2006; 67: 1062–1073
- Hughes G. F., McElnay J. C., Hughes C. M., McKenna P. Abuse/misuse of non‐prescription drugs. Pharmacy World Science 1999; 21: 251–255
- Inciardi J. A., Surratt H. L., Kurtz S. P., Cicero T. J. Mechanisms of prescription drug diversion among drug‐involved club‐ and street‐based populations. Pain Medicine 2007; 8: 171–183
- Joranson D. E., Gilson A. M. Regulatory barriers to pain management. Seminars in Oncology Nursing 1998; 14: 158–163
- MacDonald D., Neville D., Priddle M. Community pharmacists' expectations of a pharmacy network: a baseline evaluation. Canadian Pharmacy Journal 2005; 138: 50–58
- Manchikanti L. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician 2006; 9: 287–321
- McCabe S. E., Cranford J. A., Boyd C. J., Teter C. J. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addiction Behaviour 2007; 32: 562–575
- Monga N., Rehm J., Fischer B., Brissette S., Bruneau J., El Guebaly N., et al. Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug Alcohol Dependency 2007; 88: 1–8
- Neutel C. I. The epidemiology of long‐term benzodiazepine use. International Review of Psychiatry 2005; 17: 189–197
- Newfoundland, Labrador Pharmacy Board. Guidelines for the supply of exempted codeine products. 2004
- Office of National Drug Control Policy. Heroin Facts & Figures. 2006, Office of national Drug Control Policy [On‐line]. Available at: http://www.whitehousedrugpolicy.gov/drugfact/heroin/index.html
- Oxycontin Task Force. Oxycontin Task Force, final report. 2004, Accessed from http://www.health.gov.nl.ca/health/publications/oxyfinal/OxyContinFinalReport.pdf
- Patton D., Adlaf E. M. Canadian Addiction Survey (CAS): A national survey of Canadians' use of alcohol and other drugs: Prevalence of harms: Detailed report. Canadian Center on Substance Abuse, Ottawa 2005
- PMP Bulletin, NSPMP. Prescription monitoring in Nova Scotia. 2006
- PMP Bulletin, NSPMP. Patient Information. 2007
- Popova S., Rehm J., Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health 2006; 120: 320–328
- Poulin C. Medical and nonmedical stimulant use among adolescents: From sanctioned to unsanctioned use. Canadian Medical Association Journal 2001; 165: 1039–1044
- Prince Edward Island Pharmacy Board. Guidelines for the supply of exempted codeine products. 2004
- Rehm J., Baliunas D., Brochu S., Fischer B., Gnam W., Patra J., et al. The costs of substance abuse in Canada. 2006
- Richard J., Reidenberg M. M. The risk of disciplinary action by state medical boards against physicians prescribing opioids. Journal of Pain Symptom Management 2005; 29: 206–212
- Ritter A., Di Natale R. The relationship between take‐away methadone policies and methadone diversion. Drug and Alcohol Review 2005; 24: 347–352
- Sibbald B. Tighten Ontario's methadone program states inquest. Canadian Medical Association Journal 2005; 172: 319–320
- Simoni‐Wastila L., Tompkins C. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Substance Use and Misuse 2001; 36: 1275–1296
- Sproule B. A., Busto U. E., Somer G., Romach M. K., Sellers E. M. Characteristics of dependent and nondependent regular users of codeine. Journal of Clinical Psychopharmacology 1999; 19: 367–372
- Standard of Pharmacy Practice adopted by the Newfoundland and Labrador Pharmacy Board. 2004, Guidelines for the supply of exempted codeine products. Avaliable on line: http://www.nlpb.ca/Ducuments/Standards_Policies_Guidelines/SOPP‐Exempted_Products‐June2007.pdf
- Standard of Pharmacy Practice adopted by the PEI Pharmacy Board. 2004, Guidelines for the supply of exempted codeine products. Avaliable on line: http://www.napra.org/provinces/pe/Approved‐Guidelines‐for‐Codeline.pdf
- Strang D., Rashiq S. The illicit sale of prescribed opioid medications in Edmonton. Pain Research Management 2005; 10: 188–189
- Tjepkema M. Alcohol and illicit drug dependence. Health Reports 2004; 15((Suppl))9–19
- Wall R., Rehm J., Fischer B., Brands B., Gliksman L., Stewart J., et al. Social costs of untreated opioid dependence. Journal of Urban Health 2000; 77: 688–722
- Wardman D., Khan N., El Guebaly N. Prescription medication use among an aboriginal population accessing addiction treatment. Canadian Journal of Psychiatry 2002; 47: 355–360
- Weekes J., Rehm J., Mugford R. Prescription drug abuse FAQs. 2007, Canadian Centre on Substance Abuse. Ottawa, Ontario, Canada
- Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non‐medical use and abuse: position statement. Drug and Alcohol Dependence 2003; 69: 215–232